Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

ARS Pharmaceuticals, Inc. - Common Stock (NQ:SPRY)

4.110 -0.040 (-0.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,885,783
Open 4.100
Bid (Size) 4.050 (200)
Ask (Size) 4.200 (100)
Prev. Close 4.150
Today's Range 4.100 - 4.200
52wk Range 4.100 - 13.15
Shares Outstanding 95,568,307
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire

Performance

YTD
-64.2%
-64.2%
1 Month
-35.6%
-35.6%
3 Month
-58.8%
-58.8%
6 Month
-49.7%
-49.7%
1 Year
-58.6%
-58.6%

More News

Read More
News headline image
Kaplan Fox & Kilsheimer LLP Reminds Investors of a Securities Class Action Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and Lead Plaintiff Deadline on October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Class Action Reminder: ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Lead Plaintiff Deadline is October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
From Shareholders Foundation, Inc.
Via Business Wire
News headline image
Bragar Eagel & Squire, P.C. Reminds ARS Pharmaceuticals Investors to Contact the Firm Before October 5th Seeking Lead Plaintiff Role
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Shareholder Alert: Deadline to Lead in the Securities Fraud Lawsuit Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is October 5, 2026
Via NewMediaWire
Topics Fraud Lawsuit Retirement
News headline image
Kaplan Fox Deadline Alert: ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors Have Until October 5, 2026 to Seek a Lead Plaintiff Role
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Continues to Remind ARS Pharmaceuticals Inc. (NASDAQ: SPRY) Investors of the Lead Plaintiff Deadline on October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
ARS Stock Drop: Robbins LLP Reminds Investors They May Be Eligible to Lead the Class Action Against ARS Pharmaceuticals Inc.
Via Newsfile
Topics Lawsuit
News headline image
Kaplan Fox Continues to Alert Investors of a Securities Class Action Deadline on October 5, 2026 Against ARS Pharmaceuticals Inc. (NASDAQ: SPRY)
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
From Pomerantz LLP
Via GlobeNewswire
News headline image
ARS Pharmaceuticals to Participate in Upcoming Investor Conferences
From ARS Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Kaplan Fox Continues to Alert Investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) to a Class Action Deadline on October 5, 2026
Via NewMediaWire
Topics Lawsuit Retirement
News headline image
ARS PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against ARS Pharmaceuticals and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Robbins LLP Urges Investors of ARS Pharmaceuticals Inc. to Contact the Firm for Information About the SPRY Securities Class Action Lawsuit
From Robbins LLP
Via Business Wire

Frequently Asked Questions

Is ARS Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, ARS Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does ARS Pharmaceuticals, Inc. - Common Stock trade on?
ARS Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for ARS Pharmaceuticals, Inc. - Common Stock is SPRY on the Nasdaq Stock Market
What is the current price of ARS Pharmaceuticals, Inc. - Common Stock?
The current price of ARS Pharmaceuticals, Inc. - Common Stock is 4.110
When was ARS Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of ARS Pharmaceuticals, Inc. - Common Stock was at 09/18/26 04:00 PM ET
What is the market capitalization of ARS Pharmaceuticals, Inc. - Common Stock?
The market capitalization of ARS Pharmaceuticals, Inc. - Common Stock is 392.79M
How many shares of ARS Pharmaceuticals, Inc. - Common Stock are outstanding?
ARS Pharmaceuticals, Inc. - Common Stock has 393M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.